WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: neoadjuvant_guidance_rels, Neoadjuvant therapy refers_to Systemic therapy, Pathologic complete response (pCR) refers_to Absence of any residual invasive cancer, Pathologic complete response (pCR) is_measured_by Hematoxylin and eosin evaluation, Neoadjuvant therapy has_goal Breast conservation, Neoadjuvant therapy modifies Tissue biomarkers, Efficacy endpoint has_component Clinical complete response (cCR), Pathologic complete response (pCR) provides_evidence_for Overall survival in patients receiving neoadjuvant therapy, Pathologic complete response (pCR) starts_after_end_of Neoadjuvant therapy, Neoadjuvant therapy has_goal Eliminate regional nodal involvement, Neoadjuvant therapy has_goal Improved cosmesis, Neoadjuvant therapy has_goal Discontinue ineffective therapy, High-risk is_summarized_by Appropriately validated genomic measures, Sampled ipsilateral lymph nodes has_pertinent_information Axillary lymph node status, Neoadjuvant therapy has_synonym Preoperative therapy, Neoadjuvant therapy has_goal Evaluate tumor response, Patient response to therapy has_pertinent_information Supplemental prognostic information, High-risk is_summarized_by Conventional histologic features, Pathologic complete response (pCR) provides_evidence_for Disease free survival in patients receiving neoadjuvant therapy, Early-stage breast cancer refers_to Invasive breast cancer without distant metastases, Neoadjuvant therapy has_goal Reduce the risk of breast cancer recurrence